332 related articles for article (PubMed ID: 36205192)
1. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
[TBL] [Abstract][Full Text] [Related]
2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
4. COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma.
Fang W; Gan Y; Zhang L; Xiong J
Front Oncol; 2022; 12():853026. PubMed ID: 35574298
[TBL] [Abstract][Full Text] [Related]
5. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
7. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
Wang Y; Liu T; Zhang K; Huang RH; Jiang L
Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
[TBL] [Abstract][Full Text] [Related]
10. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
11. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
12. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
13. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
16. LINC01614 is a promising diagnostic and prognostic marker in HNSC linked to the tumor microenvironment and oncogenic function.
Tian X; Hu D; Wang N; Zhang L; Wang X
Front Genet; 2024; 15():1337525. PubMed ID: 38655053
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
18. The prognostic values and immune characteristics of polo-like kinases (PLKs) family: A pan-cancer multi-omics analysis.
Shen C; Wang T; Li K; Fu C; Yang S; Zhang Z; Wu Z; Li Z; Li Z; Lin Y; Zhang Y; Guo J; Fan Z; Hu H
Heliyon; 2024 Apr; 10(7):e28048. PubMed ID: 38560150
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
[Next] [New Search]